Skip to main content

Red Tree Management, LLC

13F filer · CIK 0002055980
Reported Jul 22, 2026
Net seller this quarter
13F portfolio value$147MU.S. long equity reported on 13F
Positions30 new · 0 closed
Net flow last quarter-$208KBuys minus sells
Top 10 positions weight100.0%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Jul 22, 20263 positions
BCAXBicara Therapeutics Inc.$93.9M63.77%4.80%-0.2%Q4 2024
CBLLCeribell, Inc.$42.9M29.13%5.77%Not reportedQ4 2024
CTNMContineum Therapeutics, Inc.$10.5M7.10%2.76%Not reportedQ4 2024
Q1 2026Reported Apr 22, 20263 positions
BCAXBicara Therapeutics Inc.$63.1M56.39%4.84%Not reportedQ4 2024
CBLLCeribell, Inc.$40.4M36.15%5.83%Not reportedQ4 2024
CTNMContineum Therapeutics, Inc.$8.33M7.45%2.76%Not reportedQ4 2024
Q4 2025Reported Feb 11, 20263 positions
BCAXBicara Therapeutics Inc.$53.4M48.94%5.60%Not reportedQ4 2024
CBLLCeribell, Inc.$48.4M44.37%5.88%Not reportedQ4 2024
CTNMContineum Therapeutics, Inc.$7.29M6.69%2.76%Not reportedQ4 2024
Q3 2025Reported Nov 7, 20253 positions
BCAXBicara Therapeutics Inc.$50.1M60.39%5.81%Not reportedQ4 2024
CBLLCeribell, Inc.$25.3M30.57%5.95%Not reportedQ4 2024
CTNMContineum Therapeutics, Inc.$7.5M9.04%2.28%Not reportedQ4 2024
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.